{"doi":"10.1111/ejh.13553","title":"A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre‐ibrutinib era","abstract":"OBJECTIVE: Opportunistic infections in chronic lymphocytic leukemia (CLL) have been described in clinical trials, single-center studies, and case reports. We performed a nationwide study to estimate the incidence and impact of inpatient opportunistic infections. METHODS: The incidence rate (IR) and incidence rate ratio (IRR) for Swedish CLL patients diagnosed 1994-2013, and matched controls were calculated, as well as the case-fatality ratio (CFR). RESULTS: Among 8989 CLL patients, a total of 829 opportunistic infections were registered (IR 16.6 per 1000 person-years) compared with 252 opportunistic infections in 34 283 matched controls (IR 0.99). The highest incidence in the CLL cohort was for Pneumocystis pneumonia (200 infections, IR 4.03); Herpes zoster (146 infections, IR 2.94), and Pseudomonas (83 infections, IR 1.66) infections. The highest risk relative to matched controls was observed for Pneumocystis pneumonia (IRR 114, 95% confidence interval 58.7-252). The 60-day CFR for CLL patients with opportunistic infections was 23% (188/821), highest for progressive multifocal encephalopathy (5/7, 71%) and aspergillosis (25/60, 42%). CONCLUSION: We have uniquely depicted the incidence of rare and serious infections in CLL patients and found a relatively high incidence of Pneumocystis pneumonia. Of the most common opportunistic infections, CLL patients with aspergillosis had the poorest prognosis.","journal":"European Journal Of Haematology","year":2020,"id":89524,"datarank":0.6922568671321048,"base_score":2.302585092994046,"endowment":2.302585092994046,"self_citation_contribution":0.3453877639491069,"citation_network_contribution":0.34686910318299785,"self_endowment_contribution":0.3453877639491069,"citer_contribution":0.34686910318299785,"corpus_percentile":71.06830664500657,"corpus_rank":3741,"citation_count":9,"citer_count":9,"citers_with_citation_signal":9,"citers_with_endowment":9,"datacite_reuse_total":0,"is_dataset":true,"is_dataset_confidence":0.762,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":453793,"name":"Gauti Kjartan Gíslason","orcid":null,"position":1,"is_corresponding":false},{"id":452694,"name":"Sigrún Þorsteinsdóttir","orcid":"0000-0001-5017-3530","position":2,"is_corresponding":false},{"id":452695,"name":"Sæmundur Rögnvaldsson","orcid":"0000-0003-2162-8414","position":3,"is_corresponding":false},{"id":452696,"name":"Magnús Gottfreðsson","orcid":"0000-0003-2465-0422","position":4,"is_corresponding":false},{"id":38471,"name":"Thor Aspelund","orcid":"0000-0002-7998-5433","position":5,"is_corresponding":false},{"id":452697,"name":"Ingemar Turesson","orcid":"0000-0002-4115-8010","position":6,"is_corresponding":false},{"id":453794,"name":"Magnus Björkholm","orcid":null,"position":7,"is_corresponding":false},{"id":254707,"name":"Ola Landgren","orcid":"0000-0001-6485-4839","position":8,"is_corresponding":false},{"id":452698,"name":"Sigurður Y. Kristinsson","orcid":"0000-0002-4964-7476","position":9,"is_corresponding":false},{"id":452693,"name":"Vilhjálmur Steingrímsson","orcid":"0000-0002-9385-2960","position":0,"is_corresponding":true}],"reference_count":53,"raw_metadata":null,"created_at":"2026-07-18T22:02:27.195966Z","pmid":"33211356","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}